Aciont gets grant for macular degeneration study

The NIH and the National Eye Institute are backing new research to determine if a non-invasive technology can be used to deliver Avastin and Lucentis as a treatment for age-related macular degeneration. Aciont will use the $214,000 grant to study delivering the therapies with the Visulex ocular application. Release